Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Snap (SNAP) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Snap between April 29, 2025, to August 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar E ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all individuals and entities who purchased or otherwise acquired Cytokinetics, Incorporated (NASDAQ: CYTK) (“Cytokinetics” or the “Company”) securities between December 27, 2023, and May 6, 2025 (the “Class Period”). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATIO ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all individuals and entities who purchased or otherwise acquired Cytokinetics, Incorporated (NASDAQ: CYTK) (“Cytokinetics” or the “Company”) securities between December 27, 2023, and May 6, 2025 (the “Class Period”). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATIO ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Savara To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIR ...

NEW YORK and NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has continued its investigation into United Natural Foods, Inc. (“United Natural” or the “Company”) (NYSE: UNFI). In March 2023, the Company disclosed year-over-year declines of $6 million in gross profit and over 71% in net income and earnings per diluted share for its fiscal 2023 second quarter, despit ...

NEW YORK and NEW ORLEANS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has continued its investigation into agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL). On January 5, 2024, the Company disclosed that it was slashing its 2023 profit forecasts, specifically, lowering its 2023 Medical Margin expectation to “$340 million to $360 million, approximately $110 milli ...

Accessibility StatementSkip Navigation NEW YORK CITY and NEW ORLEANS, Sept. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has continued its investigation into United Natural Foods, Inc. ("United Natural" or the "Company") (NYSE: UNFI). Contact:Kahn Swick & Foti, LLCLewis Kahn, Managing Partner[email protected]1-877-515-18501100 Poydras St., Suite 960New Orleans, LA 70163 CONNECT WITH ...

公司财务表现 - 公司大幅下调2023年医疗利润率预期至3.4亿至3.6亿美元 较先前指引降低约1.1亿美元[1] - 预期医疗成本超支9000万美元 导致利润指引下调[1] 管理层变动 - 首席财务官Timothy Bensley宣布退休 将于年内更换[1] 法律调查进展 - 公司及部分高管因涉嫌在集体诉讼期间未披露重大信息被提起证券集体诉讼[2] - 法院部分驳回公司驳回动议 允许案件继续审理[2] - Kahn Swick & Foti律师事务所正在调查公司高管及董事是否违反 fiduciary duty 或触犯州/联邦法律[2] 调查机构背景 - Kahn Swick & Foti为全美顶尖证券诉讼精品律师事务所 合作伙伴包括路易斯安那州前总检察长[3] - 该律所根据和解总价值被SCAS列为全美前十强原告律师事务所[3][4] - 服务对象包括机构投资者和零售投资者 专注于上市公司欺诈或不当行为导致的投资损失追偿[3]

诉讼背景 - 律师事务所Levi & Korsinsky代表在2023年10月30日至2025年5月20日期间购买V F Corporation证券的投资者提起集体诉讼[1] - 诉讼案件号为Sharon Brenton v V F Corporation et al (Case No 1:25-cv-02878) 由美国科罗拉多州地方法院受理[1] - 投资者可通过指定网址或联系方式获取案件信息并申请成为首席原告 截止日期为2025年11月12日[2][3][6] 指控内容 - 公司被指控在Vans品牌转型计划中发布重大虚假和误导性陈述 并隐瞒不利事实[4] - 公司未披露需要采取额外重大重置行动才能使Vans品牌恢复增长 导致该品牌收入增长轨迹出现重大挫折[4] - 这些行为导致投资者以被人为抬高价格购入公司证券[4] 财务表现 - Vans品牌2025年第四季度收入同比下降20% 较前一季度8%的跌幅进一步恶化[5] - 公司承认业绩低于预期 并将原因归咎于"为消除无盈利能力业务而刻意减少收入"及"先前未公布的额外 deliberate actions"[5] - 公司表示若不考虑这些刻意行动 Vans品牌收入仍会出现"高个位数百分比"下降[5] 市场反应 - 公司股价从2025年5月20日收盘价14.43美元/股跌至5月21日12.15美元/股[5] - 单日跌幅达15.8% 市值出现显著缩水[5]

公司业务与收购 - 公司为制药、生物技术和化学行业开发建模与仿真软件工具 [2] - 2024年6月收购模拟学习、智能与合规解决方案提供商Pro-ficiency Holdings公司 [2] - 管理层曾宣称该收购将使总目标市场翻倍并对销售产生实质贡献 [3] 财务与内部控制问题 - 公司2025年4月15日聘请Grant Thornton为新审计师 [4] - 2025年6月11日公布疲软的2025财年第三季度初步业绩 归因于市场不确定性、资金问题、药品价格和潜在关税等重大阻力 [4] - 2025年7月14日财报确认与先前收购相关的7720万美元减值支出 [5] - 次日宣布解聘Grant Thornton 并承认无法及时完成分部报告、报告单元确定及萨班斯-奥克斯利法案404(a)条要求的财务报告内部控制评估 [5] - 审计师表示已就分部报告、报告单元确定及财务报告内部控制问题向管理层和审计委员会提出异议且未获解决 [5] 股价表现 - 2025年6月11日业绩公布后股价从26.44美元/股跌至20.05美元/股 单日下跌6.39美元（跌幅24%） [4] - 2025年7月14-15日减值支出及审计师解聘消息公布后股价从17.47美元/股跌至12.97美元/股 单日下跌4.50美元（跌幅26%） [5] 法律调查 - 证券律师事务所Bleichmar Fonti & Auld LLP宣布对公司涉嫌违反联邦证券法行为展开调查 [1] - 该律所曾代表原告在特斯拉案中追回9亿美元 在Teva制药案中追回4.2亿美元 [8]